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Abstract
Differentiating between Parkinson’s disease (PD) and atypical Parkinsonism (AP) is clinically relevant but challenging. A timely and
correct diagnosis might result in better targeted treatment strategies, adequate patient counseling, and early recognition of disease-specific
complications. We aimed to investigate whether cerebrospinal fluid (CSF) concentrations of -synuclein are of additional diagnostic value.
We examined 142 consecutive patients with parkinsonism, mean disease duration 39.7 mo (Parkinson’s disease (PD), n  58; MSA, n 
47; dementia with Lewy bodies (DLB), n  3; VaP, n  22; progressive supranuclear palsy (PSP), n  10; CBD, n  2). Gold standard
as the clinical diagnosis established after 2 years of clinical follow-up. CSF concentrations of -synuclein, blood pigments and the
erythrocyte count were determined. No differences between CSF -synuclein concentrations of patients with PD with the reference values
from our laboratory were observed. We neither found significant differences between patients with PD and AP nor between AP subgroups.
Adjustment for age, disease severity or presence of erythrocytes or blood pigments in CSF did not alter these results. Our results imply that
CSF -synuclein is currently unsuitable as biomarker to differentiate between PD and AP.
2012 Elsevier Inc.
www.elsevier.com/locate/neuaging
Open access under the Elsevier OA license.b
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l1. Introduction
The differentiation between idiopathic PD and atypical
Parkinsonism (AP) is important but can be challenging. A
timely and correct diagnosis might result in better targeted
treatment strategies, adequate patient counseling and—per-
haps most importantly—early recognition of disease-spe-
cific complications. It would be helpful to identify new
biomarkers that facilitate the differential diagnosis in pa-
tients with early stages of parkinsonism.
Interestingly, a recent study showed markedly lower levels
of -synuclein in the cerebrospinal fluid (CSF) of patients with
PD as compared with controls (Hong et al., 2010). However,
the potential use of -synuclein as a biomarker for the differ-
ntiation between different forms of parkinsonism has not yet
* Corresponding author. Tel.: 0031 24 3615192; fax: 0031 24 3668754.
E-mail address: m.verbeek@neuro.umcn.nl. (M.M. Verbeek).
0197-4580 © 2012 Elsevier Inc.
doi:10.1016/j.neurobiolaging.2010.12.001
Open access under the Elsevier OA license.een studied rigorously. Here, we aimed to investigate whether
SF concentrations of -synuclein might facilitate this diag-
nostic challenge.
2. Methods
We recruited 142 consecutive outpatients with a hypo-
kinetic-rigid syndrome and an uncertain clinical diagnosis
between January 2003 and December 2006. All patients
received a lumbar puncture and a cerebral MRI scan (see
Supplementary methods).
CSF concentrations of -synuclein and blood pig-
ents and the total erythrocyte count were determined
see Supplementary methods). The method of -synuclein
nalysis and its validation has been published previously
van Geel et al., 2008). Prior to data analysis, data were
og-transformed to obtain a normal distribution for -sy-nuclein.
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Fifty-eight patients had a final clinical diagnosis of PD, 47
of multisystem atrophy (MSA) (25 possible, 20 probable and 2
definite MSA), 3 of DLB (2 possible, 1 probable DLB), 22 of
vascular parkinsonism (VaP), 10 of PSP (6 possible, 3 proba-
ble and 1 definite PSP) and 2 of corticobasal degeneration
(CBD). Clinical and demographical data of the subjects are
reported in Table 1 of the Supplementary Materials.
We observed no significant differences in CSF -sy-
uclein concentrations between patients with PD and our
eference values. We neither found differences in the -sy-
nuclein concentrations between the PD and AP groups, nor
between the different subgroups of AP (Table 1). Further-
more, we observed no differences in -synuclein concen-
ration when the group of -synucleinopathies (PD, MSA
nd DLB) was compared with the group of tauopathies (PSP
nd CBD). Additional adjustments for age, disease severity
r the presence of erythrocytes or blood pigments in the
SF did not change these results. Analyzing patients with
nly probable or definite diagnosis, and/or analyzing only
atients who completed the entire follow up duration did not
hange our results. More details of the analyses are pre-
ented in the Supplementary results.
. Discussion
Our study is the first to assess the value of CSF
-synuclein concentrations in differentiating between PD
nd AP. Despite the large sample-size, we found no
ifferences in -synuclein concentrations between differ-
nt patient groups. Furthermore, we could not replicate
he previously reported decrease in CSF -synuclein con-
centration in patients with PD as compared with controls
(Hong et al., 2010). These findings suggest that -sy-
nuclein has no value as biomarker for the differential
diagnosis of parkinsonism.
The comparability previous research investigating CSF
-synuclein levels is hindered by different assays used for
the detection of -synuclein and differences in demographic
ata of included patients en controls. Consequently, the data
n CSF -synuclein concentrations in previous studies have
been conflicting. Furthermore, if any, the observed differ-
ences were small, (Hong et al., 2010; Mollenhauer et al.,
2008; Tokuda et al., 2006) with profound overlap between
the different patients groups.
In our specialized movement disorder center, referral and
selection bias may have prompted the inclusion of an atyp-
ical patient population which may have led to more diag-
nostic uncertainty. Furthermore, the clinical diagnosis was
confirmed neuropathologically in only 3 cases, and there-
fore susceptible to misclassification. However, our gold
standard diagnosis was based on careful clinical assessment
at baseline and after 2 y of clinical follow-up, including
response to treatment and baseline cerebral MRI in all
patients. Ta
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430.e3M.B. Aerts et al. / Neurobiology of Aging 33 (2012) 430.e1–430.e3In conclusion, despite the aforementioned drawbacks,
our results imply that CSF -synuclein is currently not
advocated as a diagnostic biomarker for the differentiation
between PD and AP.
Appendix. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.neurobiolaging.
2010.12.001.
References
Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D.,
Jankovic, J., Zabetian, C.P., Leverenz, J.B., Baird, G., Montine, T.J.,
Hancock, A.M., Hwang, H., Pan, C., Bradner, J., Kang, U.J., Jensen,P.H., Zhang, J., 2010. DJ-1 and alpha-synuclein in human
cerebrospinal fluid as biomarkers of Parkinson. Brain 133, 713–726.
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T.F., Pepivani,
I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H.A., McLean, P.J.,
Trenkwalder, C., Sarracino, D.A., Vonsattel, J.P., Locascio, J.J., El-
Agnaf, O.M., Schlossmacher, M.G., 2008. Direct quantification of CSF
alpha-synuclein by ELISA and first cross-sectional study in patients
with neurodegeneration. Exp. Neurol. 213, 315–325.
Tokuda, T., Salem, S.A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi,
M.M., Locascio, J.J., Schlossmacher, M.G., El-Agnaf, O.M., 2006.
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals
and subjects with Parkinson’s disease. Biochem. Biophys. Res. Com-
mun. 349, 162–166.
van Geel, W.J., Abdo, W.F., Melis, R., Williams, S., Bloem, B.R., Ver-
beek, M.M., 2008. A more efficient enzyme-linked immunosorbent
assay for measurement of alpha-synuclein in cerebrospinal fluid.
J. Neurosci. Methods 168, 182–185.
